Gene

MAPK1

mitogen-activated protein kinase 1

Explore in graph →CI-GENE-00012010HGNC:6871 ENSG00000100030 NCBI 5594 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (5)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–5 of 5 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
MAPK1 Amplification1
WZ4002	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Resistance	4	accepted

Cohorts

Alteration frequency by cohort (29)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved29 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Colorectal Cancer (MSK, Cancer Discovery 2022) coadread_mskresistance_2022	Colorectal Adenocarcinoma	Ssm	8

Literature

Linked publications (2)

25 per page, newest first.

pubmedPublishedShowing 1–2 of 2 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.
· JAMA Oncol · 2015 · PMID 26181029 · validated civic_curation pubmed
Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.
· Cancer Discov · 2012 · PMID 22961667 · validated civic_curation pubmed

MAPK1 E278E1
Erlotinib	Head and Neck Squamous Cell Carcinoma	Predictive	C	Supports Sensitivity Response	—	submitted	EID4607 A stage IVA head and neck squamous cell carcinoma patient with MAPK1 E322K mutation was reported to be sensitive to erlotinib treatment. The patient was treated with erlotinib monotherapy daily for 13… (full text at CIViC) PMID 26181029 · Van Allen et al., 2015 · Open in CIViC	civic

MAPK1 E278E1

Erlotinib

Head and Neck Squamous Cell Carcinoma

Predictive

Supports Sensitivity Response

—

submitted

EID4607

A stage IVA head and neck squamous cell carcinoma patient with MAPK1 E322K mutation was reported to be sensitive to erlotinib treatment. The patient was treated with erlotinib monotherapy daily for 13… (full text at CIViC)

PMID 26181029 · Van Allen et al., 2015 · Open in CIViC

civic

MAPK1 E322K3
(oncogenic)	Malignant NeoplasmALIAS	Oncogenic	D	Supports Oncogenicity	4	submitted	EID12995 MAPK1 (ERK2) p.Glu322Lys (NM_002745.5:c.964G>A) rescues the anti-proliferative effects of trametinib (MEK inhibitor) in A375 cells (6 replicates). PMID 27760319 · Brenan et al., 2016 · Open in CIViC	civic
Erlotinib	Head and Neck Squamous Cell Carcinoma	Predictive	C	Supports Sensitivity Response	4	accepted	EID791 Case report of a patient with stage IVA HNSCC with near-complete histologic response after 13 days of neoadjuvant erlotinib. Whole-exome sequencing of the pre-treatment tumor revealed a MAPK1 E322K mu… (full text at CIViC) PMID 26181029 · Van Allen et al., 2015 · Open in CIViC	civic
〃	Head and Neck Squamous Cell Carcinoma	Predictive	D	Supports Sensitivity Response	—	submitted	EID4797 In an in vitro study, a HSC-6 cell line expressing MAPK1 E322K mutation was associated with sensitivity to erlotinib treatment, compared to Cal33 cells expressing wild-type MAPK1. Sensitivity was dete… (full text at CIViC) PMID 27004400 · Wen et al., 2016 · Open in CIViC	civic

MAPK1 E322K3

(oncogenic)

Malignant NeoplasmALIAS

Oncogenic

Supports Oncogenicity

submitted

EID12995

MAPK1 (ERK2) p.Glu322Lys (NM_002745.5:c.964G>A) rescues the anti-proliferative effects of trametinib (MEK inhibitor) in A375 cells (6 replicates).

PMID 27760319 · Brenan et al., 2016 · Open in CIViC

civic

Erlotinib

Head and Neck Squamous Cell Carcinoma

Predictive

Supports Sensitivity Response

accepted

EID791

Case report of a patient with stage IVA HNSCC with near-complete histologic response after 13 days of neoadjuvant erlotinib. Whole-exome sequencing of the pre-treatment tumor revealed a MAPK1 E322K mu… (full text at CIViC)

PMID 26181029 · Van Allen et al., 2015 · Open in CIViC

civic

〃

Head and Neck Squamous Cell Carcinoma

Predictive

Supports Sensitivity Response

—

submitted

EID4797

In an in vitro study, a HSC-6 cell line expressing MAPK1 E322K mutation was associated with sensitivity to erlotinib treatment, compared to Cal33 cells expressing wild-type MAPK1. Sensitivity was dete… (full text at CIViC)

PMID 27004400 · Wen et al., 2016 · Open in CIViC

civic